Organization · Venture Capital
AMR Action Fund
The AMR Action Fund is a venture capital fund dedicated to investing in antimicrobial therapeutics, focusing on companies developing treatments for drug-resistant pathogens. It aims to address the global health crisis of antimicrobial resistance.
Overview
What AMR Action Fund does
What AMR Action Fund is
The AMR Action Fund is a venture capital fund dedicated to investing in antimicrobial therapeutics, focusing on companies developing treatments for drug-resistant pathogens. It aims to address the global health crisis of antimicrobial resistance.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- March 19, 2026
Official channels
Find AMR Action Fund elsewhere
Open the official website or a supported primary organization account.
Capability profile
AMR Action Fund as a funder
Investment thesis
The AMR Action Fund addresses the global health crisis of antimicrobial resistance by investing in clinical-stage companies developing innovative therapeutics. The fund aims to launch 2-4 new antibiotics by 2030, bridging the market failure in antibiotic development with significant backing from major pharmaceutical companies.
Focus narrative
The AMR Action Fund invests in small and mid-size biotechnology companies that are developing treatments for priority pathogens identified by the World Health Organization and the Centers for Disease Control and Prevention. The fund emphasizes clinical-stage investments in both traditional small-molecule antibiotics and innovative modalities, such as bacteriophages and antibody treatments, while advocating for market reforms to enhance the value and accessibility of lifesaving drugs.
Value beyond capital
The AMR Action Fund provides not only capital but also strategic access to a powerful network of over 20 leading pharmaceutical companies. This unique positioning allows portfolio companies to engage with potential partners and acquirers, enhancing their chances of success in the competitive landscape of antimicrobial therapeutics.
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Regions
- Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 11
Portfolio context
Notable portfolio companies include: BioVersys: Focused on therapies for drug-resistant pathogens. BiomX: Advancing phage therapies targeting specific pathogenic bacteria. Venatorx Pharmaceuticals: Developing a beta-lactam/beta-lactamase inhibitor combination for urinary tract infections. Vedanta Biosciences: Creating drugs based on consortia of commensal bacteria for preventing recurrent C. difficile infections. Pattern Bioscience: Developing a diagnostics platform for rapid identification of bacterial pathogens. Antabio: Targeting drug-resistant pathogens. Utility Therapeutics: Recently received FDA approval for a new urinary tract infection treatment. Elion Therapeutics: Developing antifungals for high-priority fungal pathogens. TenNor Therapeutics: Specializing in therapies against bacterial infections. F2G: Developing therapies for invasive fungal infections. Peptilogics: Creating peptide therapeutics for medical device-related infections.
Common questions
What to know about AMR Action Fund
Upseed classifies AMR Action Fund under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 19, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.